Recent advances in the use of cell-penetrating peptides for medical and biological applications☆

Fonseca, Sonali B.; Pereira, Mark P.; Kelley, Shana O.

doi:10.1016/j.addr.2009.06.001

Cited by 510 publications

(423 citation statements)

References 116 publications

Supporting

Mentioning

409

Contrasting

Unclassified

Order By: Relevance

“…Examples of the potential therapeutic applications of PTD-based delivery, in contrast, have already been proposed. 189,190 On the other hand, larger complexes may benefit from sedimentation onto the cells and have the advantage of known increases in transfection efficiency with lower toxicity due to the requirement of decreased amounts of transfection reagent. A major problem of PTD-based delivery is its general inefficiency and endosomal entrapment.…”

Section: ©2 0 1 1 L a N D E S B I O S C I E N C E D O N O T D I S Tmentioning

confidence: 99%

Targeting antibodies to the cytoplasm

Marschall

Frenzel

Schirrmann

et al. 2011

mAbs

111

View full text Add to dashboard Cite

Section: ©2 0 1 1 L a N D E S B I O S C I E N C E D O N O T D I S Tmentioning

confidence: 99%

Targeting antibodies to the cytoplasm

Marschall

Frenzel

Schirrmann

et al. 2011

mAbs

111

View full text Add to dashboard Cite

“…Various nanoparticles since then were designed and developed, including poly(ethylene oxide)-poly(L-lactic acid)/poly(b-benzyl-L-aspartate), poly(lactideco-glycolide)-[(propylene oxide)-poly(ethylene oxide)], polyphosphazene derivatives, poly(ethylene glycol)-coated nanospheres, azidothymidin (AZT)/dideoxycytidine (ddc) nanoparticles, poly (isobutylcynoacrylate) nanocapsules, poly(g-benzyl-L-glutamate)/poly(ethylene oxide), chitosan-poly(ethylene oxide) nanoparticles, methotrexate-o-carboxymethylate chitosan, solid lipid nanoparticles (SLNs), and so on (Blasi et al 2009;Caruso et al 2010;Chekhonin et al 2009;Fonseca et al 2009;Gilmore et al 2008;Graf et al 2009;Huynh et al 2009;Jatariu et al 2009;Kaur et al 2008;Khalil and Mainardes 2009;Ljubimova et al 2008;Mistry et al 2009b;Modi et al 2010;Namdeo et al 2008;Shilpi et al 2007;Tosi et al 2008;Wong et al 2010). Further to these polymer nanoparticles, there are metal-based, lipid-based, and biological nanoparticles.…”

Section: Variety Of Nanoparticlesmentioning

confidence: 99%

Nanomaterials in controlled drug release

Cai

2011

Cytotechnology

View full text Add to dashboard Cite

In past years with the advances of chemistry and material sciences, the development of nanotechnology brought generations of nanomaterials with specific biomedical properties. These include the nanoparticle-based drug delivery, nanosized drugs, and nanomaterials for tissue engineering. The present article focuses on the use of nanomaterials in controlled drug release. The applications of nanomaterials with nanoenabled drug release characteristics brought many benefits when compared to the traditional (bulk) materials. We discuss the current advances and propose some future directions for the technology development.

show abstract

“…It is one of the well-studied cell-penetrating peptides. Tat is a group of short peptides sharing the ability of translocation across several biological membranes and can also carry various macromolecular cargoes such as proteins, antibodies, toxins, oligonucleotides, DNA, imaging agents and nanoparticles through membranes without affecting the activity of the cargoes (Gupta et al, 2005;Hansen et al, 2008;Fonseca et al, 2009;Koren et al, 2011). In this present study, the physical properties, chemical stability and hypoglycemic activity of the insulin-Tat mixture loaded in niosomes were investigated and evaluated for the oral delivery efficacy of this mixture.…”

Section: Introductionmentioning

confidence: 99%

Hypoglycemic activity and stability enhancement of human insulin–tat mixture loaded in elastic anionic niosomes

et al. 2016

View full text Add to dashboard Cite

This study aimed to investigate the synergistic effect of trans-activator of transcription (Tat) and niosomes for the improvement of hypoglycemic activity of orally delivered human insulin. The elastic anionic niosomes composing of Tween 61/cholesterol/dicetyl phosphate/sodium cholate at 1:1:0.05:0.02 molar ratio loaded with insulin-Tat mixture (1:3 molar ratio) was prepared. Deformability of the elastic anionic niosomes decreased after loaded with the mixture of 1.35 times. For the in vitro release, the insulin (T 10 ¼ 4 h) loaded in the elastic anionic niosomes indicated the slower release rate than insulin in the mixture (T 10 ¼ 3 h) loaded in niosomes. At room temperature (30 ± 2 C), the mixture loaded in elastic anionic niosomes was more chemical stable than the free mixture of 1.3, 1.4 and 1.7 times after stored for 4, 8 and 12 weeks, respectively. Oral administration in the alloxan-induced diabetic mice of the mixture loaded in elastic anionic niosomes with the insulin doses at 25, 50 and 100 IU/kg body weight indicated significant hypoglycemic activity with the percentage fasting blood glucose reduction of 1.95, 2.10 and 2.10 folds of the subcutaneous insulin injection at 12 h, respectively. This study has demonstrated the synergistic benefits of Tat and elastic anionic niosomes for improving the hypoglycemic activity of the orally delivered human insulin as well as the stability enhancement of human insulin when stored at high temperature. The results from this study can be further developed as an effective oral insulin delivery.

show abstract

Recent advances in the use of cell-penetrating peptides for medical and biological applications☆

Cited by 510 publications

References 116 publications

Targeting antibodies to the cytoplasm

Targeting antibodies to the cytoplasm

Nanomaterials in controlled drug release

Hypoglycemic activity and stability enhancement of human insulin–tat mixture loaded in elastic anionic niosomes

Contact Info

Product

Resources

About